Department of Pediatrics, Division of Medical Genetics, Los Angeles Biomedical Research Institute, Harbor-UCLA Medical Center , Torrance, CA , USA ; Department of Pediatrics, David Geffen School of Medicine, University of California, LA , USA.
Department of Pediatrics, Division of Medical Genetics, Los Angeles Biomedical Research Institute, Harbor-UCLA Medical Center , Torrance, CA , USA.
PeerJ. 2014 May 27;2:e403. doi: 10.7717/peerj.403. eCollection 2014.
Background. Nasal continuous positive airway pressure (nCPAP) is a widely accepted technique of non-invasive respiratory support in premature infants with respiratory distress syndrome due to lack of lung surfactant. If this approach fails, the next step is often intubation, mechanical ventilation (MV) and intratracheal instillation of clinical lung surfactant. Objective. To investigate whether aerosol delivery of advanced synthetic lung surfactant, consisting of peptide mimics of surfactant proteins B and C (SP-B and SP-C) and synthetic lipids, during nCPAP improves lung function in surfactant-deficient rabbits. Methods. Experimental synthetic lung surfactants were produced by formulating 3% Super Mini-B peptide (SMB surfactant), a highly surface active SP-B mimic, and a combination of 1.5% SMB and 1.5% of the SP-C mimic SP-Css ion-lock 1 (BC surfactant), with a synthetic lipid mixture. After testing aerosol generation using a vibrating membrane nebulizer and aerosol conditioning (particle size, surfactant composition and surface activity), we investigated the effects of aerosol delivery of synthetic SMB and BC surfactant preparations on oxygenation and lung compliance in saline-lavaged, surfactant-deficient rabbits, supported with either nCPAP or MV. Results. Particle size distribution of the surfactant aerosols was within the 1-3 µm distribution range and surfactant activity was not affected by aerosolization. At a dose equivalent to clinical surfactant therapy in premature infants (100 mg/kg), aerosol delivery of both synthetic surfactant preparations led to a quick and clinically relevant improvement in oxygenation and lung compliance in the rabbits. Lung function recovered to a greater extent in rabbits supported with MV than with nCPAP. BC surfactant outperformed SMB surfactant in improving lung function and was associated with higher phospholipid values in bronchoalveolar lavage fluid; these findings were irrespective of the type of ventilatory support (nCPAP or MV) used. Conclusions. Aerosol delivery of synthetic lung surfactant with a combination of highly active second generation SP-B and SP-C mimics was effective as a therapeutic approach towards relieving surfactant deficiency in spontaneously breathing rabbits supported with nCPAP. To obtain similar results with nCPAP as with intratracheal instillation, higher dosage of synthetic surfactant and reduction of its retention by the delivery circuit will be needed to increase the lung dose.
鼻持续气道正压通气(nCPAP)是一种广泛应用的无创呼吸支持技术,适用于因肺表面活性物质缺乏而出现呼吸窘迫综合征的早产儿。如果这种方法失败,下一步通常是插管、机械通气(MV)和气管内滴注临床肺表面活性剂。目的:研究在 nCPAP 中雾化输送由表面活性蛋白 B 和 C(SP-B 和 SP-C)肽模拟物和合成脂质组成的高级合成肺表面活性剂是否可以改善表面活性物质缺乏的兔子的肺功能。方法:通过配制 3% Super Mini-B 肽(SMB 表面活性剂)、一种高表面活性 SP-B 模拟物和 1.5% SMB 和 1.5% SP-C 模拟物 SP-Css 离子锁 1(BC 表面活性剂)的组合,生产实验性合成肺表面活性剂,与合成脂质混合物。在使用振动膜雾化器进行气溶胶生成测试和气溶胶调理(粒径、表面活性剂组成和表面活性)后,我们研究了雾化输送合成 SMB 和 BC 表面活性剂制剂对盐水冲洗、表面活性物质缺乏的兔子的氧合和肺顺应性的影响,这些兔子分别在 nCPAP 或 MV 的支持下。结果:表面活性剂气溶胶的粒径分布在 1-3 µm 分布范围内,且气溶胶化不影响表面活性剂的活性。在相当于早产儿临床表面活性剂治疗剂量(100mg/kg)的情况下,两种合成表面活性剂制剂的雾化输送都能迅速且具有临床相关性地改善兔子的氧合和肺顺应性。在接受 MV 支持的兔子中,肺功能的恢复程度大于接受 nCPAP 支持的兔子。BC 表面活性剂在改善肺功能方面优于 SMB 表面活性剂,并且与支气管肺泡灌洗液中的更高磷脂值相关;这些发现与所使用的通气支持类型(nCPAP 或 MV)无关。结论:用高度活跃的第二代 SP-B 和 SP-C 模拟物组合雾化输送合成肺表面活性剂是一种有效的治疗方法,可以缓解接受 nCPAP 支持的自主呼吸兔子的表面活性物质缺乏。为了在 nCPAP 中获得与气管内滴注相似的结果,需要增加合成表面活性剂的剂量,并减少输送回路对其的保留,以增加肺剂量。